Literature DB >> 7608505

An overview of nosocomial infection control in Brazil.

C S Pannuti1, R S Grinbaum.   

Abstract

Brazil is the largest country in Latin America, with a population of 146 million people. The socioeconomic development and the distribution of population and health services varies widely within the country. There are approximately 1.2 million hospital admissions per month, 80% of them paid by a government healthcare program that follows the diagnosis-related groups (DRGs) model. The Ministry of Health has been trying to establish a nationwide nosocomial infection control program since 1983. Most Brazilian hospitals now have some kind of infection control activity, but only a few of them have complete programs. Infrastructural deficiencies, the scarcity of well-trained healthcare workers, and the widespread occurrence of multiresistant Staphylococcus aureus and gram-negative bacteria are some of the challenges faced by Brazilian hospitals in the control of nosocomial infection.

Entities:  

Mesh:

Year:  1995        PMID: 7608505     DOI: 10.1086/647080

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  3 in total

1.  Surgical site infection: rates, etiology and resistance patterns to antimicrobials among strains isolated at Rio de Janeiro University Hospital.

Authors:  K R Santos; L S Fonseca; G P Bravo Neto; P P Gontijo Filho
Journal:  Infection       Date:  1997 Jul-Aug       Impact factor: 3.553

2.  Evaluation of Calendula officinalis as an anti-plaque and anti-gingivitis agent.

Authors:  Mayur Sudhakar Khairnar; Babita Pawar; Pramod Parashram Marawar; Ameet Mani
Journal:  J Indian Soc Periodontol       Date:  2013-11

3.  Antiplaque and antigingivitis effects of a gel containing Punica granatum Linn extract: a double-blind clinical study in humans.

Authors:  Alexandre Daher Yunes Salgado; Juliana Lemos Maia; Sérgio Luís da Silva Pereira; Telma Leda Gomes de Lemos; Olívia Morais de Lima Mota
Journal:  J Appl Oral Sci       Date:  2006-06       Impact factor: 2.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.